EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

Autor: Kerstin Westman, Mark A. Little, Richard A. Watts, Julia U Holle, Bruno Crestani, Augusto Vaglio, Peter A. Merkel, Bernhard Hellmich, Ingeborg M. Bajema, Max Yates, John Mills, Thomas H. Hauser, David Jayne, Chetan Mukhtyar, Maria C. Cid, Nilüfer Yalçındağ, Vladimir Tesar, Alfred Mahr, Martin Laudien, Mårten Segelmark, Janice Mooney, Raashid Luqmani
Přispěvatelé: Universitat de Barcelona
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Biopsy
Social and Clinical Pharmacy
0302 clinical medicine
Quality of life
Blood vessels
Recurrence
Systemic vasculitis
Immunology and Allergy
030212 general & internal medicine
Disease management (health)
Vasos sanguinis
Plasma Exchange
Adrenocortical hormones
Remission Induction
Disease Management
Retreatment
Rituximab
Protocols clínics
Vasculitis
Immunosuppressive Agents
medicine.drug
medicine.medical_specialty
Immunology
education
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
General Biochemistry
Genetics and Molecular Biology
03 medical and health sciences
Rheumatology
Internal medicine
medicine
Humans
Corticosteroids
Intensive care medicine
Disease Activity
Cyclophosphamide
030203 arthritis & rheumatology
business.industry
Samhällsfarmaci och klinisk farmaci
Evidence-based medicine
medicine.disease
Corticosteroides
Medical protocols
Treatment
business
Rheumatism
Zdroj: Recercat. Dipósit de la Recerca de Catalunya
instname
Annals of the Rheumatic Diseases, 75(9), 1583-1594
Dipòsit Digital de la UB
Universidad de Barcelona
DOI: 10.1136/annrheumdis-2016-209133
Popis: Podeu consultar la correcció d'errades a: http://dx.doi.org/10.1136/annrheumdis-2016-209133corr1
In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in life-threatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.
Databáze: OpenAIRE
Externí odkaz: